These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

623 related articles for article (PubMed ID: 15105901)

  • 21. Correlation between dosimetric parameters and late rectal and urinary toxicities in patients treated with high-dose-rate brachytherapy used as monotherapy for prostate cancer.
    Konishi K; Yoshioka Y; Isohashi F; Sumida I; Kawaguchi Y; Kotsuma T; Adachi K; Morimoto M; Fukuda S; Inoue T
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1003-7. PubMed ID: 19345517
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Technological advances in radiotherapy for the treatment of localised prostate cancer.
    Mangar SA; Huddart RA; Parker CC; Dearnaley DP; Khoo VS; Horwich A
    Eur J Cancer; 2005 Apr; 41(6):908-21. PubMed ID: 15808957
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Feasibility and toxicity of a single fraction high-dose-rate brachytherapy followed by a course of EBRT for localized prostate cancer: a retrospective study. The Polyclinique Courlancy experience].
    Mallet F; Wdowczyk D; Bruna A; Villena P; Herard A; Amory JP; Joffroy P; Pangrazzi T
    Cancer Radiother; 2010 Jan; 14(1):11-8. PubMed ID: 20005765
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biochemical response after 3-d conformal radiotherapy of localized prostate cancer to a total dose of 66 gy 4-year results.
    Wachter-Gerstner N; Wachter S; Goldner G; Nechvile E; Pötter R
    Strahlenther Onkol; 2002 Oct; 178(10):542-7. PubMed ID: 12386785
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term outcome of high dose rate brachytherapy in radiotherapy of localised prostate cancer.
    Aström L; Pedersen D; Mercke C; Holmäng S; Johansson KA
    Radiother Oncol; 2005 Feb; 74(2):157-61. PubMed ID: 15734203
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acute toxicity of conformal high dose interstitial brachytherapy boost in prostate cancer.
    Soumarová R; Homola L; Stursa M; Perková H
    Neoplasma; 2006; 53(5):410-7. PubMed ID: 17013535
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combined modality treatment with high-dose-rate brachytherapy boost for locally advanced prostate cancer.
    Hsu IC; Cabrera AR; Weinberg V; Speight J; Gottschalk AR; Roach M; Shinohara K
    Brachytherapy; 2005; 4(3):202-6. PubMed ID: 16182220
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination external beam radiation and brachytherapy boost with androgen suppression for treatment of intermediate-risk prostate cancer: an initial report of CALGB 99809.
    Hurwitz MD; Halabi S; Ou SS; McGinnis LS; Keuttel MR; Dibiase SJ; Small EJ
    Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):814-9. PubMed ID: 18407435
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stereotactic body radiotherapy as monotherapy or post-external beam radiotherapy boost for prostate cancer: technique, early toxicity, and PSA response.
    Jabbari S; Weinberg VK; Kaprealian T; Hsu IC; Ma L; Chuang C; Descovich M; Shiao S; Shinohara K; Roach M; Gottschalk AR
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):228-34. PubMed ID: 21183287
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical outcome after treatment with a brachytherapy boost versus external beam boost for anal carcinoma.
    Oehler-Jänne C; Seifert B; Lütolf UM; Studer G; Glanzmann C; Ciernik IF
    Brachytherapy; 2007; 6(3):218-26. PubMed ID: 17681244
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High-dose-rate brachytherapy boost to the dominant intra-prostatic tumor region: hemi-irradiation of prostate cancer.
    Schick U; Popowski Y; Nouet P; Bieri S; Rouzaud M; Khan H; Weber DC; Miralbell R
    Prostate; 2011 Sep; 71(12):1309-16. PubMed ID: 21308714
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An eight-year experience of HDR brachytherapy boost for localized prostate cancer: biopsy and PSA outcome.
    Bachand F; Martin AG; Beaulieu L; Harel F; Vigneault E
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):679-84. PubMed ID: 18963537
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Six year experience of external beam radiotherapy, brachytherapy boost with a 1Ci (192)Ir source, and neoadjuvant hormonal manipulation for prostate cancer.
    Izard MA; Haddad RL; Fogarty GB; Rinks A; Dobbins T; Katelaris P
    Int J Radiat Oncol Biol Phys; 2006 Sep; 66(1):38-47. PubMed ID: 16904516
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High-dose-rate brachytherapy without external beam irradiation for locally advanced prostate cancer.
    Yoshioka Y; Konishi K; Oh RJ; Sumida I; Yamazaki H; Nakamura S; Nishimura K; Nonomura N; Okuyama A; Inoue T
    Radiother Oncol; 2006 Jul; 80(1):62-8. PubMed ID: 16870289
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High-dose-rate brachytherapy and external-beam radiotherapy for hormone-naïve low- and intermediate-risk prostate cancer: a 7-year experience.
    Aluwini S; van Rooij PH; Kirkels WJ; Jansen PP; Praag JO; Bangma CH; Kolkman-Deurloo IK
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1480-5. PubMed ID: 22285661
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combined brachytherapy with external beam radiotherapy for localized prostate cancer: reduced morbidity with an intraoperative brachytherapy planning technique and supplemental intensity-modulated radiation therapy.
    Zelefsky MJ; Nedelka MA; Arican ZL; Yamada Y; Cohen GN; Shippy AM; Park JJ; Zaider M
    Brachytherapy; 2008; 7(1):1-6. PubMed ID: 18299108
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Feasibility of high-dose-rate brachytherapy salvage for local prostate cancer recurrence after radiotherapy: the University of California-San Francisco experience.
    Lee B; Shinohara K; Weinberg V; Gottschalk AR; Pouliot J; Roach M; Hsu IC
    Int J Radiat Oncol Biol Phys; 2007 Mar; 67(4):1106-12. PubMed ID: 17197119
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase II dose escalation study of image-guided adaptive radiotherapy for prostate cancer: use of dose-volume constraints to achieve rectal isotoxicity.
    Vargas C; Yan D; Kestin LL; Krauss D; Lockman DM; Brabbins DS; Martinez AA
    Int J Radiat Oncol Biol Phys; 2005 Sep; 63(1):141-9. PubMed ID: 16111582
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical outcome in patients with prostate cancer treated with external beam radiotherapy and high dose-rate iridium 192 brachytherapy boost: a 6-year follow-up.
    Kälkner KM; Wahlgren T; Ryberg M; Cohn-Cedermark G; Castellanos E; Zimmerman R; Nilsson J; Lundell M; Fowler J; Levitt S; Hellström M; Nilsson S
    Acta Oncol; 2007; 46(7):909-17. PubMed ID: 17917823
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Unification of a common biochemical failure definition for prostate cancer treated with brachytherapy or external beam radiotherapy with or without androgen deprivation.
    Fitch DL; McGrath S; Martinez AA; Vicini FA; Kestin LL
    Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1430-9. PubMed ID: 16765527
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.